Thibaut Biography
After studying Pharmacy and receiving his PhD in Pharmaceutical Chemistry at the University of Tübingen, Germany, Ulrich Thibaut started his industrial career as a sales representative and scientific advisor at Evans & Sutherland – a high end 3D computer graphics company based in Salt Lake City and Munich – in 1991. After a successful year in sales he decided to go back to scientific research and joined Byk Gulden GmbH, a mid-sized pharmaceutical company in Konstanz, Germany as head of the scientific molecular modeling laboratory.
For several years he engaged in lead optimization projects in the therapeutic areas of Gastroenterology, Anti-Inflammation and Oncology and was promoted to Senior Research Scientist in 1996. During that time, together with his colleagues numerous new compound patents were filed and granted. In 1999 he became Head of Department of an evolving Department of Chemo- and Bioinformatics, which inter alia ran all preclinical scientific information systems and also the quickly growing compound library for high throughput screening. After the change of the legal structure of Byk Gulden, which became ALTANA Pharma AG in 2002, he was asked to lead the entire discovery research organization of the group and was promoted to Corporate Vice President. In 2005 he became Executive Vice President and a Member of the Board of Management of ALTANA Pharma AG, with worldwide responsibility for R&D, Regulatory Affairs, Drug Safety and Intellectual Property.
After ALTANA Pharma AG had been sold to Nycomed AG in late 2006, he moved to the medical device industry and joined Drägerwerk AG in Lübeck as Chief Technology Officer and Member of the Board of Management in 2007. For more than 3 years he was responsible for all R&D organizations of the Dräger Group – namely Dräger Medical, Dräger Safety and the Basic Research Unit, as well as the global Intellectual Property organization of the group. With a strong emphasis he led the Dräger Medical Development groups through difficult times with substantial reorganization efforts and, together with his leadership team, formed an integrated, project- and portfolio-management oriented organization which successfully developed new and highly profitable generations of medical devices for anesthesia, respiratory support and intensive care patient monitors as well as respirators and incubators for prematurely born babies.
After studying Pharmacy and receiving his PhD in Pharmaceutical Chemistry at the University of Tübingen, Germany, Ulrich Thibaut started his industrial career as a sales representative and scientific advisor at Evans & Sutherland – a high end 3D computer graphics company based in Salt Lake City and Munich – in 1991. After a successful year in sales he decided to go back to scientific research and joined Byk Gulden GmbH, a mid-sized pharmaceutical company in Konstanz, Germany as head of the scientific molecular modeling laboratory.
For several years he engaged in lead optimization projects in the therapeutic areas of Gastroenterology, Anti-Inflammation and Oncology and was promoted to Senior Research Scientist in 1996. During that time, together with his colleagues numerous new compound patents were filed and granted. In 1999 he became Head of Department of an evolving Department of Chemo- and Bioinformatics, which inter alia ran all preclinical scientific information systems and also the quickly growing compound library for high throughput screening. After the change of the legal structure of Byk Gulden, which became ALTANA Pharma AG in 2002, he was asked to lead the entire discovery research organization of the group and was promoted to Corporate Vice President. In 2005 he became Executive Vice President and a Member of the Board of Management of ALTANA Pharma AG, with worldwide responsibility for R&D, Regulatory Affairs, Drug Safety and Intellectual Property.
After ALTANA Pharma AG had been sold to Nycomed AG in late 2006, he moved to the medical device industry and joined Drägerwerk AG in Lübeck as Chief Technology Officer and Member of the Board of Management in 2007. For more than 3 years he was responsible for all R&D organizations of the Dräger Group – namely Dräger Medical, Dräger Safety and the Basic Research Unit, as well as the global Intellectual Property organization of the group. With a strong emphasis he led the Dräger Medical Development groups through difficult times with substantial reorganization efforts and, together with his leadership team, formed an integrated, project- and portfolio-management oriented organization which successfully developed new and highly profitable generations of medical devices for anesthesia, respiratory support and intensive care patient monitors as well as respirators and incubators for prematurely born babies.
Thibaut Biography
Thibaut Biography
Thibaut Biography
Thibaut Biography
Thibaut Biography
Thibaut Biography
Thibaut Biography
Thibaut Biography
Thibaut Biography
Thibaut Courtois
Thibaut Biography
Thibaut Courtois At Atlético Madrid
No comments:
Post a Comment